Skip to main content
. Author manuscript; available in PMC: 2016 May 4.
Published in final edited form as: Expert Opin Pharmacother. 2014 Sep 29;15(16):2443–2459. doi: 10.1517/14656566.2014.965142

Table 1.

Major Phase II studies of bortezomib monotherapy in mantle cell lymphoma.

Ref. Bortezomib dose and schedule No. of patients No. of prior therapies Results
[24,76] 1.3 mg/m2 on days 1, 4, 8, 11 (every 21 days) 155 treated, 141 assessable for response 1 (median) 33% ORR, 8% CR/CRu, median TTP 6.7 months, median OS 23.5 months, median DOR 9.2 months
[77] 1.3 mg/m2 on days 1, 4, 8, 11 (every 21 days) 29 (13 previously untreated) 0 in 13, 1 in 11, 2 in 5 46.4% ORR, 1 CRu, median DOR 10 months
[78] 1.5 mg/m2 on days 1, 4, 8, 11 (every 21 days)* 40 2 47% ORR (5 CRs)
*

Dose reductions to 1.3 and 1.1 mg/m2 were allowed.

CR: Complete response; CRu: Unconfirmed complete response; DOR: Duration of response; ORR: Overall response rate; OS: Overall survival; TTP: Time to progression.